Research Update - Predicting Progression in Multiple Myeloma

Updated: Sep 30, 2020

Mark Bustoros, MD, discusses how the use of genomic predictors in multiple myeloma (MM) allows for a better understanding of who will progress.

VIDEO: :49 Seconds

These risk models provide a way classify patients' needs according to their risks.

It also helps doctors and clinicians gain more accurately predict who is most likely to progress. By understanding the risks, patients and providers can work together more closely to determine the best approach to treatment.

This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Dana-Farber Cancer Insitute logo
Harvard University School of Public Health logo
Stand Up To Cancer logo
Broad Institute logo
Johns Hopkins University logo
Mayo Clinic logo

© 2018 Dana-Farber Cancer Institute, Boston MA | United States |  Terms of Use  |   Privacy Policy